Sanofi (SNYNF)
OTCMKTS
· Delayed Price · Currency is USD
103.00
+1.67 (1.65%)
Jun 6, 2025, 2:48 PM EDT
Sanofi Revenue
Sanofi had revenue of 10.61B EUR in the quarter ending March 31, 2025, a decrease of -4.61%. This brings the company's revenue in the last twelve months to 45.17B, down -2.42% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.17B EUR
Revenue Growth
-2.42%
P/S Ratio
2.51
Revenue / Employee
544.97K EUR
Employees
82,878
Market Cap
122.65B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Sanofi News
- 18 hours ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY - GlobeNewsWire
- 1 day ago - Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact - Seeking Alpha
- 1 day ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY - Accesswire
- 2 days ago - Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan - GlobeNewsWire
- 2 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY - Accesswire
- 3 days ago - BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC - Business Wire
- 3 days ago - Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector - GlobeNewsWire
- 4 days ago - Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines - GlobeNewsWire